Biohaven Ltd. (BHVN) – What Are Researchers Saying About This Stock?

Shares of Biohaven Ltd. (NYSE:BHVN) have received a consensus recommendation of “Moderate Buy” from the sixteen brokerages that are covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, four have issued a hold recommendation, eight have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $20.80.

Several research firms have recently commented on BHVN. Canaccord Genuity Group raised their price objective on Biohaven from $21.00 to $32.00 and gave the stock a “buy” rating in a research note on Friday, October 30th. Raymond James Financial reiterated a “strong-buy” rating on shares of Biohaven in a research note on Thursday, October 8th. TD Cowen reissued a “buy” rating on shares of Biohaven in a report on Wednesday, August 26th. Robert W. Baird set a $48.00 target price on shares of Biohaven in a research note on Thursday, October 22nd. Finally, Weiss Ratings upgraded shares of Biohaven from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, November 2nd.

Biohaven Price Performance

Shares of Biohaven stock opened at $14.42 on Monday. Biohaven has a one year low of $7.48 and a one year high of $18.24. The stock’s fifty day moving average is $13.61 and its 200 day moving average is $12.31. The stock has a market cap of $2.18 billion, a P/E ratio of -3.74 and a beta of 1.36. The company has a debt-to-equity ratio of 21.23, a quick ratio of 3.05 and a current ratio of 3.05.

Biohaven (NYSE:BHVN) last released its earnings results on Monday, August 10th. The company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.15). Sell-side analysts anticipate that Biohaven will post -3.05 earnings per share for the current year.

Institutional Trading of Biohaven

Several institutional investors and hedge funds have recently modified their holdings of the company. BlueCrest Capital Management Ltd purchased a new stake in Biohaven during the 2nd quarter valued at approximately $60,000. Sterling Capital Management LLC lifted its holdings in shares of Biohaven by 847.5% in the third quarter. Sterling Capital Management LLC now owns 4,444 shares of the company’s stock worth $59,000 after buying an additional 3,975 shares in the last quarter. IFP Advisors Inc lifted its holdings in shares of Biohaven by 43.3% in the second quarter. IFP Advisors Inc now owns 6,011 shares of the company’s stock worth $89,000 after buying an additional 1,816 shares in the last quarter. Allworth Financial LP purchased a new position in shares of Biohaven in the second quarter worth $117,000. Finally, Essential Partners LLC boosted its position in shares of Biohaven by 31.7% during the first quarter. Essential Partners LLC now owns 9,020 shares of the company’s stock worth $76,000 after acquiring an additional 2,169 shares during the last quarter. 88.78% of the stock is currently owned by institutional investors.

Biohaven News Summary

Here are the key news stories impacting Biohaven this week:

• Positive Sentiment: Biohaven says a pivotal Phase 3 trial of BHV-1300 for Graves’ disease is underway and presented three research posters at the American Thyroid Association meeting. The program could address a disease with few recent treatment advances, though trial progress is not a guarantee of success. Biohaven Graves’ disease Phase 3 and ATA announcement
• Positive Sentiment: HC Wainwright raised several future EPS estimates, including narrowing its projected losses for 2026–2029 and forecasting positive EPS in 2030. These revisions may bolster expectations for longer-term financial improvement.
• Positive Sentiment: A separate report says a Morgan Stanley analyst expects BHVN shares to rise, adding a favorable analyst signal; the article headline does not provide the rationale or target. Morgan Stanley analyst outlook
• Negative Sentiment: Despite its improved forecasts, HC Wainwright maintained a Neutral rating and a $10 price target, below the recent share price—suggesting that the analyst sees downside relative to current levels.

Biohaven Company Profile

Biohaven Ltd. (NYSE:BHVN) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for neurological and neuropsychiatric diseases, as well as certain immunological and rare disorders. The company’s research activities include small-molecule medicines, monoclonal antibodies and other innovative therapeutic approaches.

Biohaven’s pipeline has included investigational treatments for conditions such as migraine, obsessive-compulsive disorder, spinal muscular atrophy, amyotrophic lateral sclerosis, mood disorders and autoimmune diseases.